Eli Lilly ends Q1 on a high note on the heels of positive obesity trial data

Lilly announced on Thursday morning that Q1 numbers are in, and revenue grew by just under 15%. Much of the focus, however, was on the tirzepatide, an experimental GIP and GLP-1 receptor agonist made up of a single peptide, for obesity. Novo Nordisk originally challenged Lilly last year after showing that its diabetes drug Wegovy, responsible for more than a billion dollars in sales, was effective at treating non-diabetic adults with obesity.